Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von HC Wainwright 

Celldex Therapeutics diskutieren

Celldex Therapeutics

WKN: A2PEAB / Symbol: CLDX / Name: Celldex / Aktie / Biotechnologie & medizinische Forschung / Micro Cap /

32,40 €
2,53 %

Einschätzung Buy
Rendite (%) -26,04 %
Kursziel 60,65
Veränderung
Endet am 09.09.25

Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $67.00 price target on the stock.
Ratings data for CLDX provided by MarketBeat

Einschätzung Buy
Rendite (%) -26,42 %
Kursziel 60,23
Veränderung
Endet am 16.09.25

Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $67.00 price target on the stock.
Ratings data for CLDX provided by MarketBeat

Einschätzung Buy
Rendite (%) -4,05 %
Kursziel 45,76
Veränderung
Endet am 25.09.25

Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "outperform" rating re-affirmed by analysts at Wolfe Research. They now have a $51.00 price target on the stock.
Ratings data for CLDX provided by MarketBeat

Einschätzung Buy
Rendite (%) -4,70 %
Kursziel 71,72
Veränderung
Endet am 26.09.25

Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Ratings data for CLDX provided by MarketBeat

Celldex Therapeutics, Inc. (NASDAQ: CLDX) was upgraded by analysts at Wells Fargo & Company from a "hold" rating to a "strong-buy" rating.
Ratings data for CLDX provided by MarketBeat

Der Beitrag wird untersucht